ClinicalTrials.Veeva

Menu

Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer (UCL-Xenog)

C

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Status

Enrolling

Conditions

Squamous Cell Carcinoma of the Head and Neck

Treatments

Procedure: Local biopsy in the tumor

Study type

Observational

Funder types

Other

Identifiers

NCT02572778
UCL-ONCO2015-02

Details and patient eligibility

About

The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to:

generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer

  • perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors
  • evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options
  • evaluate biomarkers of drug sensitivity
  • study primary and secondary (acquired) resistance in these models

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent
  • Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available
  • Follow-up data should be available
  • Patients with recurrent disease are allowed
  • Written informed consent

Trial contacts and locations

1

Loading...

Central trial contact

Aline Gillain, MedSciences; Sandra Schmitz, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems